Navacim pMHC nanomedicines (PVT101 / PVT201 platform)

Overview

Navacims (PVT101 for Type 1 Diabetes; PVT201 for autoimmune liver disease; PVT401 for celiac/inflammatory bowel disease) are a class of off-the-shelf peptide–major histocompatibility complex (pMHC)-coated iron-oxide nanomedicines developed by Parvus Therapeutics based on more than two decades of foundational immunology by Dr. Pere Santamaria at the University of Calgary and IDIBAPS Barcelona (PMID: 26886799, PMID: 37153608).

Unlike conventional tolerogenic vaccines (such as CNP-103 or ASITI-201) that deliver free autoantigen peptides to antigen-presenting cells (APCs) for processing and presentation, a Navacim nanoparticle directly displays a dense, oriented array of recombinant autoantigen peptide–MHC class II (pMHCII) molecules on a pegylated iron-oxide nanoparticle core without costimulatory molecules (CD80/CD86).

When these pMHCII nanoparticles bind in high density to the T-cell receptors (TCRs) of antigen-experienced autoreactive CD4+ T cells (specifically pathogenic T-follicular helper [Tfh] precursor cells that have already been primed by pancreatic beta-cell destruction, while sparing naive T cells), sustained TCR cross-linking in the absence of costimulation triggers rapid transcriptional reprogramming (PMID: 37153608, PMID: 40066448). The pathogenic autoreactive T cells convert in vivo into LAG-3+ CD49b+ IL-10- and TGF-$\beta$-secreting Type 1 regulatory T (Tr1) cells. Once localized to the pancreas and pancreatic lymph nodes, these antigen-specific Tr1 cells recruit regulatory B (Breg) cells and tolerogenic dendritic cells that suppress autoreactive T-cell responses against all local beta-cell antigens ("infectious bystander tolerance"), without impairing systemic immunity to vaccines or infections.

Preclinical T1D Evidence & Clinical Pipeline Status (PVT101 vs PVT201 & PVT401)

1. Preclinical Reversal of Diabetes in Mice (Nature 2016, Frontiers in Immunology 2023)

• In the landmark 2016 Nature paper (Clemente-Casares et al., PMID: 26886799) and subsequent 2023 transcriptional studies (Solé et al., PMID: 37153608), intravenous administration of nanoparticles coated with T1D-relevant pMHCII complexes (such as BDC2.5mi/IAg7 or insulin B-chain epitopes) expanded cognate Tr1 cells in diabetic NOD mice and humanized mice reconstituted with human T1D lymphocytes, restoring durable normoglycemia without systemic immunosuppression.

2. Critical Distinction Between PVT101 (T1D) and PVT201 / PVT401 (Liver & Celiac Trials)

• T1D Program (PVT101 — Partnered with Novartis, Preclinical): In April 2017, Parvus signed an exclusive worldwide license and collaboration agreement with Novartis to develop and commercialize PVT101, its Type 1 Diabetes Navacim candidate. However, as of October 2026, PVT101 has not yet entered a registered human clinical trial on ClinicalTrials.gov, and zero human C-peptide or glycemic efficacy data have been reported in people with T1D (who continue to rely on exogenous insulin to maintain 70–180 mg/dL [3.9–10.0 mmol/L]).
• Autoimmune Liver Disease (PVT201 — NCT06798454, Phase 1 Completed): Parvus advanced its autoimmune liver candidate PVT201 (displaying a mitochondrial pyruvate dehydrogenase PDC-E2 epitope on HLA-DRB4*01:01) through a 24-participant first-in-human Phase 1 single-ascending-dose study in Adelaide, Australia (NCT06798454, COMPLETED) in healthy volunteers and patients with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC), and cleared a US FDA IND with Orphan Drug Designation for PBC.
• Celiac & IBD Programs (PVT401 — NCT07423000, Phase 1 Recruiting): Backed by partnerships with Genentech (2019) and AbbVie (2024), Parvus is also conducting a 36-patient Phase 1 trial of PVT401 in celiac disease in Melbourne, Australia (NCT07423000, RECRUITING).

Limitations & Watch Items

1. No Human T1D Clinical Trial Yet (PVT101): While PVT201 (NCT06798454) and PVT401 (NCT07423000) validate human GMP manufacturing and Phase 1 safety of the pMHCII-iron-oxide nanoparticle architecture in other autoimmune conditions, PVT101 itself remains preclinical in Type 1 Diabetes.
2. HLA Class II Matching & Multi-Allele Formulation: Because each pMHCII construct presents its peptide in a specific human HLA class II groove (e.g., HLA-DRB1*04:01, HLA-DRB1*03:01, or HLA-DQ8), covering the broader T1D population requires either HLA genotyping for a matched construct or a multi-allele cocktail.

Summary of Strengths & Limitations

Strengths

• Off-the-shelf intravenous nanomedicine that reprograms existing antigen-experienced autoreactive T cells in vivo into LAG-3+ CD49b+ IL-10-producing Tr1 regulatory T cells and regulatory B cells without generalized immunosuppression (Clemente-Casares et al., Nature 2016)
• Triggers bystander ("infectious") tolerance across multiple islet autoantigens in diabetic NOD and humanized mouse models, restoring normoglycemia without requiring knowledge of every initiating autoantigen
• Platform safety and human pharmacodynamics are being de-risked by completed and active Phase 1 trials of sibling Navacim candidates PVT201 in autoimmune liver disease (NCT06798454) and PVT401 in celiac disease (NCT07423000)

Limitations

• Despite a 2017 worldwide license and collaboration agreement with Novartis for the T1D candidate (PVT101), no human clinical trial in Type 1 Diabetes has been registered or reported efficacy data as of October 2026
• NCT06798454 (PVT201) and NCT07423000 (PVT401) test mitochondrial PDC-E2 and gliadin pMHCII constructs in liver and celiac disease, not islet pMHCII constructs in T1D
• Requires matching recombinant peptide-MHC class II complexes to human HLA class II alleles (such as HLA-DR3, HLA-DR4, or HLA-DQ8) and periodic intravenous redosing due to short nanoparticle blood half-life